Cleveland Clinic's Main Campus is working with The Michael J Fox Foundation on a clinical research study called The Parkinson’s Progression Marker Initiative (PPMI). The goal of PPMI is to identify and assess biomarkers in people who are at risk to develop PD as well as those with typical PD symptoms. The PPMI project has various sub-studies, including one looking for non-PD patients with a reduced sense of smell.
While most people with a reduced sense of smell will not develop PD, the majority of PD patients do have reduced sense of smell. This loss of smell often begins several years prior to the onset of motor symptoms like tremor or stiffness.
You qualify to participate in this PPMI sub-study if you are over the age of 60 with a reduced sense of smell and no PD diagnosis.
The study involves up to 48 months of participation. There are approximately six visits in the first year and then a visit every 6 months until completion.
If you are interested in learning more about this trial, please contact study coordinator Jennifer Mule at 216-441-1134 or email email@example.com and reference study: PPMI.
You can also find additional information on this trial at clinicaltrials.gov: